Regulus Therapeutics' stock price doubles on Novartis's buyout offer

Regulus Therapeutics

30/04/2025 12:44

** Shares of Regulus Therapeutics RGLS.O more than double to $7.79 premarket

** Novartis offers to buy Regulus for $7/shr cash upfront and another $7/shr on hitting certain regulatory milestones for kidney disease drug farabursen

** Offer worth $800 mln on upfront price

** RGLS shares have already more than doubled this year through last close

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))